BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23230131)

  • 1. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
    Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
    Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
    Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
    Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
    Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
    Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
    J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.
    Johnson AJ; Brown MN; Black ME
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):199-204. PubMed ID: 22093835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
    Gilbert JA; Salavaggione OE; Ji Y; Pelleymounter LL; Eckloff BW; Wieben ED; Ames MM; Weinshilboum RM
    Clin Cancer Res; 2006 Mar; 12(6):1794-803. PubMed ID: 16551864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
    Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
    Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
    Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
    Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
    Kocabas NA; Aksoy P; Pelleymounter LL; Moon I; Ryu JS; Gilbert JA; Salavaggione OE; Eckloff BW; Wieben ED; Yee V; Weinshilboum RM; Ames MM
    Drug Metab Dispos; 2008 Sep; 36(9):1951-9. PubMed ID: 18556440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.